0001689375-19-000002.txt : 20191226 0001689375-19-000002.hdr.sgml : 20191226 20191226101435 ACCESSION NUMBER: 0001689375-19-000002 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20191226 DATE AS OF CHANGE: 20191226 EFFECTIVENESS DATE: 20191226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Entrada Therapeutics, Inc. CENTRAL INDEX KEY: 0001689375 IRS NUMBER: 813983399 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-328899 FILM NUMBER: 191308799 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 857-305-1825 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: CycloPorters, Inc. DATE OF NAME CHANGE: 20161104 D/A 1 primary_doc.xml X0708 D/A LIVE 0001689375 Entrada Therapeutics, Inc. 50 NORTHERN AVENUE BOSTON MA MASSACHUSETTS 02210 857-305-1825 DELAWARE CycloPorters, Inc. Corporation true 2016 Louis Tartaglia 50 Northern Avenue Boston MA MASSACHUSETTS 02210 Director Kush Parmar 50 Northern Avenue Boston MA MASSACHUSETTS 02210 Director Christine Brennan 50 Northern Avenue Boston MA MASSACHUSETTS 02210 Director Anja Harmeier 50 Northern Avenue Boston MA MASSACHUSETTS 02210 Director Dipal Doshi 50 Northern Avenue Boston MA MASSACHUSETTS 02210 Executive Officer Director Natarajan Sethuraman c/o Foley Hoag LLP 155 Seaport Blvd. Boston MA MASSACHUSETTS 02210-2600 Executive Officer Todd Foley 50 Northern Avenue Boston MA MASSACHUSETTS 02210 Director Mario Saltarelli 50 Northern Avenue Boston MA MASSACHUSETTS 02210 Executive Officer Nathan Dowden 50 Northern Avenue Boston MA MASSACHUSETTS 02210 Executive Officer John Crowley 50 Northern Avenue Boston MA MASSACHUSETTS 02210 Director Pharmaceuticals Decline to Disclose 06b true 0001531209-18-000003 2018-12-14 true true false 0 59021750 34021752 24999998 Total Offering Amount and Total Amount Sold include the conversion of outstanding indebtedness of the Issuer. A portion of the offering amount is reserved for additional closings. false 10 0 0 3382953 true The above figure is an estimate of payments for services in the ordinary course made in 2019 and expected to be made over the course of 2020. false Entrada Therapeutics, Inc. /s/ Dipal Doshi Dipal Doshi President & CEO 2019-12-26